Abstract: A medical monitoring device for monitoring electrical signals from the body of a subject is described. The medical monitoring device monitors electrical signals originating from a cardiac cycle of the subject and associates each cardiac cycle with a time index. The medical monitoring device applies a forward computational procedure to generate a risk score indicative of hyperkalemia, hypokalemia or arrhythmia of the subject. The medical monitoring device can adjust the forward computational procedure based upon clinical data obtained from the subject.

Abstract: A medical monitoring device for monitoring electrical signals from the body of a subject is described. The medical monitoring device monitors electrical signals originating from a cardiac cycle of the subject and associates each cardiac cycle with a time index. The medical monitoring device applies a forward computational procedure to generate a risk score indicative of hyperkalemia, hypokalemia or arrhythmia of the subject. The medical monitoring device can adjust the forward computational procedure based upon clinical data obtained from the subject.

Abstract: Systems and methods for recharging zirconium phosphate and zirconium oxide in reusable sorbent modules are provided. The systems and methods provide for recharging any combination of zirconium phosphate and/or zirconium oxide sorbent modules. The systems and methods also provide for linkage of multiple rechargers for sharing of infrastructure.

Abstract: Control logic and processes for monitoring and controlling sorbent rechargers are presented. The control logic and processes use control systems to monitor the rechargers for performance problems and to control the recharging process. Various sensors in communication with the control systems are provided to ensure proper operation.

Abstract: Systems and methods for recharging zirconium phosphate and zirconium oxide are provided. The systems and methods provide for recharging of the zirconium phosphate and zirconium oxide in reusable sorbent modules. The systems and methods include recharging flow paths for recharging zirconium phosphate independently or concurrently.

Abstract: Systems and methods for managing effluent from recharging zirconium phosphate and/or zirconium oxide are provided. The systems and methods control the pH of the zirconium phosphate and zirconium oxide effluent to allow for safe disposal. The systems and methods provide for management of the recharger effluent pH while recharging zirconium phosphate and zirconium oxide either independently or concurrently.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Abstract: Effective treatments of pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulindac or a pharmaceutically acceptable salt thereof at or near a target site, one can relieve pain and/or inflammation caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days, at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Abstract: Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Abstract: Effective treatments of pain that accompanies post-operative surgeries are provided. Through the administration of an effective amount of a combination of bupivacaine and clonidine at or near a target site, one can alleviate or prevent pain. This administration of bupivacaine and clonidine or pharmaceutically acceptable salts thereof is particularly useful following surgery.

Abstract: Effective treatments of acute pain for extended periods of time are provided. The treatments include the administration of one or more drug depots at or near a target site wherein the drug depots include an effective amount of clonidine formulated within a polyorthoester. By administration of one or more drug depots at or near the target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days.

Abstract: An apparatus and method for replenishing urease in a sorbent cartridge for use in sorbent dialysis. The sorbent cartridge is configured to allow an amount of urease to be added to the sorbent cartridge. A urease solution can be injected into the sorbent cartridge to replenish the urease containing module, or solid urease can be added to the sorbent cartridge. The sorbent module can also comprise other, rechargeable, sorbent materials for removing toxins other than urea from spent dialysate.

Abstract: A stacked sorbent assembly for use in sorbent dialysis. The stacked sorbent assembly contains two or more interchangeable sorbent pouches that allow for fluid to freely pass into and through the sorbent materials, while keeping the sorbent materials inside the sorbent pouches. Any of the pouches in the sorbent cartridge can be reused and/or recharged.

Abstract: An apparatus and method for replenishing urease in a sorbent cartridge for use in sorbent dialysis using urease pouches. The sorbent cartridge is configured to allow insertion of a urease pouch or injection of a urease solution into the sorbent cartridge containing a urease pouch. The sorbent module can also comprise other, rechargeable, sorbent materials for removing toxins other than urea from spent dialysate.

Abstract: An apparatus and method for replenishing urease in a sorbent cartridge for use in sorbent dialysis. The system is configured to allow insertion of a urease pouch, injection of a urease solution, or addition of a urease cartridge, into a dialysis cabinet containing a dialysis flow loop. The urease can be dissolved and the resulting urease solution added to the sorbent cartridge in the flow loop to replenish the urease within the sorbent cartridge. The sorbent cartridge can also comprise other, rechargeable, sorbent materials for removing toxins other than urea from spent dialysate.

Abstract: A reserve zirconium phosphate module for continuing dialysis in the event the capacity of the original zirconium phosphate module is exceeded. The sorbent cartridge can have a sensor for detecting when the capacity of the zirconium phosphate material has been exceeded, and a valve assembly for diverting the flow of spent dialysate into the reserve module when needed. Any of the modules of the sorbent cartridge can be reusable and the sorbent materials therein recharged.

Abstract: A customizable modular dialysate regeneration assembly with connectable sorbent packaging systems. The dialysate regeneration assembly can be customized based on patient parameters or dialysis session parameters. A processor can be included that can determine the correct amount of each sorbent material necessary for a given patient and a given dialysis session.

Abstract: A sorbent pouch for use in sorbent dialysis. The sorbent pouch allows for fluid to freely pass into and through the sorbent materials, while keeping the sorbent materials inside the sorbent pouch.

Abstract: Methods and related apparatuses for sorbent recharging are provided. The methods and related apparatuses for recharging can recharge a specific rechargeable layer of a sorbent material such as zirconium phosphate in a sorbent cartridge. The methods and apparatuses include passing solutions containing combinations of acids, bases and salts through a module containing a rechargeable sorbent material such as zirconium phosphate in order to replace ions bound to the zirconium phosphate with hydrogen and sodium ions. The method allows for a customizable zirconium phosphate, with control over the ratios of sodium to hydrogen on the recharged zirconium phosphate.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.